Initiating treatment with SGLT2 inhibitors vs GLP-1 RAs was linked to a 19% reduced risk for composite anemia outcomes in patients with T2D and CKD stages I-III.
Compared to nonusers, patients with type 2 diabetes and acute kidney disease administered SGLT-2is had a significantly lower risk of mortality, major adverse kidney events, and major adverse cardiovascular events.
Taiwan: High premature ventricular complex (PVC) burden is not linked to unfavorable maternal and neonatal outcomes without need for antiarrhythmic drugs (AADs) therapy in pregnant women having.